Virbac US is driven by a passion for enhancing the health of companion animals.
In the US, our focus is solely on meeting the unique needs of veterinary professionals caring for dogs, cats and other companion animals. We recognize that meeting those needs starts with listening.
Ultimately, the essence of Virbac US is found in our relationships with our veterinarians. It is through these relationships that, together, we can find the right answers by first asking the right questions.
More About Virbac US
Pierre-Richard Dick, a French veterinarian, creates the SARL Virbac biological research center.
We take our first steps internationally thanks to distribution partnerships in Benelux and the Federal Republic of Germany.
We develop the first insecticide collar for dogs, which would later become one of our flagship products. 
We take a new step forward with the construction of the building of our future headquarters in Carros, near Nice, quickly adding a production and storage unit and a loading dock.
We make available in France the first cephalosporin in veterinary medicine (for dogs, cats and cattle), thus providing an alternative to the cephalosporins derived from human pharmaceuticals.
In response to the viral gastroenteritis epidemic decimating dog breeding, we create the first parvovirus-based vaccine approved for dogs, thus entering the very exclusive club of innovative vaccine-developing laboratories.
The opening of our first subsidiary in Germany, following acquisition of local distributor VMG, marks the beginning of our deployment in Europe.
Number-two French animal health laboratory, we start to trade on the secondary market of the Paris stock exchange.
Virbac Corporation Established
With the acquisition of Allerderm Inc., we propel ourselves into the United States market. A specialist in the new veterinary dermatology market, we become the world leader a few years later.
By designing the first genetically engineered vaccine against feline leukemia made from a purified p45 FeLV-envelope retrovirus, we provide veterinarians with an effective solution against a disease in cats for which there was no cure at the time.
We open a new door with the acquisition of Imperial Dog, a dog and cat food manufacturer, founded by the creator of Royal Canin, now Virbac Nutrition.
In Europe, we continue to move forward by offering the first oral anti-rabies vaccine for foxes, obtained by selective mutation.
Our founder Pierre-Richard Dick, doctor of veterinary medicine, dies suddenly at the age of 55 while on a Central American sea voyage. Pascal Boissy, then financial director, succeeds him to head the company. Six months later, we adopt a new organizational structure made up of an executive board and a supervisory board, of which Jeanine Dick, wife of the founder, becomes chairwoman.
We push our international expansion further with the creation of our first subsidiary in Asia (a partnership with Maruyasu, a Japanese import-export company).
Numerous companies created to develop our company on French territory merge into a single subsidiary, Virbac France, formalizing the beginning of the Virbac umbrella brand.
Through its “I love my pet, I vaccinate it” poster campaign, we raise the general public’s awareness of vaccination in France.
Eric Marée, 48 years old, graduate of HEC and holder of an MBA from Cornell University in the United States, becomes chairman of the Virbac executive board.
Virbac Corporation Merges with Agri-Nutrition Group & Settles in Fort Worth
Thanks to the acquisition of Agri-Nutrition, a company based in St. Louis (Missouri), we acquire a range of dental care and hygiene products.
We make available to European veterinarians the first interferon omega for dogs and cats.
The Pierre-Richard Dick Foundation, created in 1993 after our founder’s death, becomes the Virbac Corporate Foundation. It aims to raise public awareness, educate and inform, especially children, about issues related to the integration and well-being of animals in cities.
We partner with Jean-Pierre Dick, son of our founder and doctor of veterinary medicine, on his sailing adventure: through his involvement in epic races, the skipper helps to enhance the veterinary profession, promote animal health and our values in the four corners of the world.
C.E.T.® Brand of Products Created
Virbac Corporation Acquires Animal Health Products from King Pharmaceuticals
Marie-Hélène Dick, daughter of our founder, doctor of veterinary medicine and MBA graduate from HEC, is named chairwoman of Virbac’s supervisory board.
We strengthen our presence with Indian veterinarians and farmers thanks to the acquisition of Agrivet Farm Care, the animal health branch of GlaxoSmithKline. A collaboration that allows us to become number 1 in this country. 
With 7 production units, we currently have an industrial park on five continents (France, United States, Mexico, Brazil, Australia, South Africa and Vietnam) to bring our health solutions ever closer to those who care for animals. 
We share with veterinarians the first deslorelin-based implant, inducing a reversible neutering in male dogs.
We sign an agreement with Pfizer Inc. to acquire the Australian rights to a range of products for food producing animals, primarily parasiticides and vaccines for cattle and sheep.
Committed to the animal proteins of the future, we acquire a majority share of Centrovet, animal health market leader in Chile, expert in the development and production of innovative products for the protection and treatment of cold water aquaculture farms (salmon and trout).
C.E.T.® Home Dental Care Celebrates 25 Years of Dental Excellence
Paul R. Hays Named President & CEO, Virbac Corporation and Area Director, North America
We acquire Schweitzer Biotech Company, a Taiwanese company that is an expert in the development of cell culture banks serving as the basis for production of viral vaccines primarily for swine and poultry. This acquisition gives the impulse to the creation of a new biology R&D structure in Southeast Asia, a region recognized for the largest swine and aquaculture (warm water) markets on the planet.
The Virbac Corporate Foundation, aware of the challenges related to the interconnection between animal, human, and environmental health, is committed to a screening, control, and prevention program for bovine tuberculosis and rabies in the Gonarezhou Park (Zimbabwe). 
Virbac announces the successful closing, on January 2nd, of its agreement with Eli Lilly and Company to acquire two major parasiticides for dogs in the United States: SENTINEL® FLAVOR TABS® and SENTINEL® SPECTRUM®, previously marketed by Novartis Animal Health.
After the building of VB8 in Carros in 2014, dedicated to the manufacture of sterile injectables, we continue to invest in quality and production capacity with the construction of Argo Navis, VB8’s alter ego in Mexico. 
Virbac US Expands in Bridgeton, Mo.
Sébastien Huron, 47 years old, doctor of veterinary medicine, head of Global Business Operations, and member of the executive board since 2012, succeeds Éric Marée as chairman of Virbac.
At the helm of St. Michel-Virbac, Jean-Pierre Dick wins his fourth Jacques Vabre Race (a first in the history of the Coffee Race). This victory marks a turning point in the life of the sailor and the most fitting closure to his 17 years of adventures around the world, flying the colors of our company. 
After the physiological range in 2016, we provide dog and cat owners with a range of dietetic petfood. Their composition is particularly suited to the dietary needs of carnivores. 
Virbac Corporation Selects Kansas City for New North American Distribution Center
Virbac Celebrates 50 Years Anniversary
Virbac Launches Supplement to Improve Survival Rates
Virbac Wins European Award
Virbac launches FR3SH Technology
We make a jump in several Asian countries thanks to a preventive solution against porcine circovirus, a virus responsible for significant losses in farms. Developed by our teams with the genotype predominant in most regions of the world, this vaccine helps limit the impact of this disease in one of the world's most important swine production areas.
François Fournier became responsible for the financial results of North America (USA, Canada) and for the area’s consolidated P&L. He leads the development and growth of Virbac businesses, industrial and supply chain operations and people in the area, in line with Virbac’s global strategy.
We moved our North American headquarters from an Meacham Blvd to the Solana complex, providing much quicker access to the airport, restaurants and other facilities. With this move, all warehousing operations also moved to the Kansas City Distriution Center. Over 75 employees enjoyed a move to the new office building and new surroundigs.
In 2020, The Every Dog Project became The Every Pet Project (EPP) in our contiuous efforts to help all animals get the proper care. The new and improved EPP has become our major Cause Marketing initiative and ocontinues to provide monetary support to two nominated charities per month ($2,500 each).
We offer to the European and North American veterinarians the first intratumoral injectable for canine mastocytomas, the second most frequently diagnosed cancer and the most common skin cancer. With this novel injectable solution, we are opening a new path in the treatment of canine skin tumors.
We announced the successful completion of its divestment of the U.S. rights to its parasiticides for dogs: SENTINEL® FLAVOR TABS® and SENTINEL® SPECTRUM® to MSD Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK). The consideration received for the transaction amounted to approximately US $400 million, subject to customary closing adjustments, settled in cash.
We acquired Clomicalm® and Itrafungol(TM) from Elanco Animal Health on a global basis and took over the product portfolio on March 1st, 2021. The addition strengthens Virbac’s existing companion animal offerings in the segments of behavior management and dermatology.
We completes the acquisition of iVet LLC, a US-based specialty pet food company. This acquisition is a transformative move for the commercial operations and will help Virbac incorporate and accelerate future product launches.
In 2022 Virbac Corporation entered the Livestock Health business segment by launching three products within six months. Two of those products, TULISSIN® (Tulathromycin injectable) Injectable Solution and TENOTRYL(TM) (enrofloxacin) injectable solution, covered a range of pathologies for both cattle and swine. These launches helped demonstrate our strong commitment to veterinarians and their customers, cattle and swine producers, and provided a strong portfolio of new alternatives to improve the health of livestock.